Table 3 Nanomaterials used for transdermal drug delivery in psoriasis treatment
From: Advances in the modulation of ROS and transdermal administration for anti-psoriatic nanotherapies
Nanomaterials | Composition | Advantages | Limitations | References |
|---|---|---|---|---|
Liposomes | Phospholipid, cholesterol, oleic acid | Encapsulation of hydrophilic and hydrophobic drug | Oxidative degradation and limited skin penetration | |
Polymers/micelles | Polyethylene glycol ligands; poly(ε-caprolactone) | Biocompatibility; stable biological activity; sustained release of encapsulated dugs; relatively long-circulating drug carriers, increased solubility of hydrophobic drugs | Relatively low drug loading capacity and highly dependent on critical micellar concentration | |
Nanoparticles | Various inorganic nanoparticles (silver, gold and cerium oxide) | Sustain the release of the drug, reduction in side effects, high drug loading capacity | Lower biocompatibility; potential skin irritation | |
Natural bioactive compound | Bilirubin, polyphenols, flavonoids, lithocholic, melatonin | Clinical translation availability, good biocompatibility | Lower hydrophobicity | |
Hydrogels | Hydrophilic polymers, gelatin, hyaluronic acid, bioactive nanoparticles and drugs used to construct hydrogels through various chemical or physical cross-links | Good hydrophilicity, biocompatibility, good moisture, retention, avoidance of the intrusion of external bacteria caused by materials’ breakage, appropriate microstructure | - | |
Microneedles | Solid, hydrogel, siRNA, drugs and polymers | Biodegradable, higher transdermal delivery efficiency | Infection-associated risks; a lack of precise drug dosage |